Thr256

Site Information
RPVYPTKtFPNHYSI SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 451402

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	breast cancer ( 2 , 3 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 3 , 5 ) , non-small cell lung cancer ( 3 , 5 )
Relevant cell line - cell type - tissue:	breast ( 1 , 2 ) , BT-549 (breast cell) ( 3 ) , H2009 (pulmonary) ( 3 ) , H2887 (pulmonary) ( 3 ) , HCC2279 (pulmonary) ( 3 ) , HUES-9 ('stem, embryonic') ( 4 ) , MDA-MB-231 (breast cell) ( 3 ) , NCI-H2172 (pulmonary) ( 3 ) , NCI-H3255 (pulmonary) ( 5 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
4	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
5	Moritz A (2010) CST Curation Set: 10598; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info